Europe — EMA

Pamidronat Hikma (Pamidronate Disodium)

Pamidronate Disodium, the active ingredient in Pamidronat Hikma, is a bis‑bisphosphonate presented as a unknown strength/unknown form for intravenous use.

Pamidronate Disodium

Request sourcing

Pack/s

What is Pamidronate Disodium?

Pamidronate Disodium, the active ingredient in Pamidronat Hikma, is a bis‑bisphosphonate presented as a unknown strength/unknown form for intravenous use. It treats abnormal bone resorption in conditions such as malignant bone disease, Paget’s disease and osteoporosis, primarily in adult patients.

GNH USA supplies Pamidronat Hikma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and oncology centres worldwide.

What is Pamidronate Disodium used for?

Pamidronate Disodium is used in several bone‑related disorders that involve excessive osteoclast activity. - Malignant bone disease: reduces the risk of skeletal‑related events and bone pain associated with metastatic cancer. - Paget’s disease of bone: helps to normalise the bone‑remodelling cycle. - Osteoporosis (severe cases): improves bone mineral density and lowers fracture risk.

What are the side effects of Pamidronate Disodium?

Common Side Effects: - ... ... ... ... ... ... ... ... ... ... ... ... ... … … … ... … ... ... ... ... ... ... ... ... ... ... ... ... ... ... ...

t t ... ... ........ .... ... ... ... ... ... ... ... ... ... ... ... ... ... ...

Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.

Send a sourcing enquiry for this product →